Hans Henrik Klouman elected to the BoD of Phoenix Solutions

The Board of Directors of Phoenix Solutions is pleased to announce that Hans Henrik Klouman (Master of Law) has been elected to the company BoD. Klouman is currently General Counsel and Senior Vice President of Statoil ASA and on the board of several companies primarily within the financial and energy industry. Klouman combines a broad legal background with deep business knowledge and international experience and have held various executive and board positions within the financial and energy sectors since he started practicing law in 1987. CEO Per Sontum; "We are very pleased to get Hans Henrik on-board with the rest of the team. With his vast legal and international business experience he will become an invaluable resource in the further development of the company”.


Phoenix Solutions AS completes its Series B financing:

The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series B financing led by current shareholder, Investinor AS and an expanded group of healthcare angel investors. CEO Per Sontum; "We are very pleased to announce this second round of financing which, including the recently awarded BIA program from RCN, will give us the ability to meet a key developmental milestone; start of a clinical phase I/IIa program for treatment of non-resectable pancreatic cancer in 2018".


Jean-Claude Provost (MD) elected to the BoD:

The Board of Directors of Phoenix Solutions is pleased to announce that Jean-Claude Provost (MD) has been elected to the company BoD. Provost is currently Global Head of Imaging R&D at GE Healthcare Life Sciences. CEO Per Sontum; "We are very pleased to get Jean-Claude on-board with the rest of the team. With his 25+ years’ experience from Clinical Research and R&D management he will add invaluable skill sets to the further development of ACT®.


Phoenix Solutions AS completes its Series A financing:

The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series A financing led by a small group of healthcare angel investors. CEO Per Sontum; "We are very pleased to announce this first round of financing. This funding will give us the ability to reach a key developmental milestone for our preclinical work in pancreatic cancer ".


Phoenix Solutions and research partners will present two papers at the 21st European symposium on Ultrasound Contrast Imaging, Rotterdam, January 2016. Come and meet us.

Sontum et al.: Acoustic Cluster Therapy - A Novel Approach for Ultrasound Mediated Targeted Drug Delivery: Technology Basics and Proof of Concept.

Bush et al.: In vivo activation, imaging dynamics and delivery effectiveness of an acoustic cluster therapy (ACT) agent.